SCHEMBL5876321

SCHEMBL5876321

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)(c2cccc(F)c2)C=C3)cc1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.34
GPR6 P46095 1/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 2/20 0.33
ADORA2A P29274 3/20 0.32
ADORA3 P0DMS8 3/20 0.32
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
ADORA1 P30542 2/20 0.31
NOD2 Q9HC29 1/20 0.31
NOD1 Q9Y239 1/20 0.31
MEN1 O00255 3/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LMNA P02545 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876550 0.98 KMT2A (0.35) KMT2AGPR6USP2MAPK1ALDH1A1
SCHEMBL5877322 0.97 GPR6 (0.36) KMT2AGPR6USP2MAPK1ALDH1A1
SCHEMBL5876629 0.94 KMT2A (0.36) KMT2AGPR6ALDH1A1MEN1L3MBTL1
SCHEMBL5876201 0.93 USP2 (0.34) KMT2AGPR6USP2MAPK1ALDH1A1
SCHEMBL5876198 0.93 USP2 (0.37) KMT2AUSP2MAPK1ALDH1A1ADORA3
SCHEMBL5877100 0.91 KMT2A (0.34) KMT2AUSP2MAPK1ALDH1A1ADORA3
SCHEMBL5876984 0.89 GPR6 (0.35) KMT2AGPR6USP2MAPK1ALDH1A1
SCHEMBL5876672 0.89 KMT2A (0.35) KMT2AALDH1A1MEN1L3MBTL1LMNA
SCHEMBL5876012 0.89 NR1H2 (0.36) KMT2AGPR6USP2MAPK1ALDH1A1
SCHEMBL5877650 0.89 CCR6 (0.36) KMT2AUSP2MAPK1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT KMT2A 2326/4885GPR6 986/4885USP2 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.